Latest news with #KingOfPrussia
Globe and Mail
08-07-2025
- Business
- Globe and Mail
Vertex to Announce Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
KING OF PRUSSIA, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release second quarter 2025 financial results before the market opens on Wednesday, August 6, 2025. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Those wishing to participate may do so by dialing 1-412-317-6026 approximately ten minutes prior to start time. A listen-only webcast of the call will also be available through the Company's Investor Relations website at A conference call replay will be available approximately one hour after the call by dialing 1-412-317-6671 and referencing passcode 10200958, or via the Company's Investor Relations website. The replay will expire on August 20, 2025 at 11:59 p.m. Eastern Time. About Vertex Vertex, Inc. is a leading global provider of indirect tax solutions. The Company's mission is to deliver the most trusted tax technology enabling global businesses to transact, comply and grow with confidence. Vertex provides solutions that can be tailored to specific industries for major lines of indirect tax, including sales and consumer use, value added and payroll. Headquartered in North America, and with offices in South America and Europe, Vertex empowers the world's leading brands to simplify the complexity of continuous compliance. For more information, visit or follow us on Twitter and LinkedIn.
Yahoo
04-07-2025
- Business
- Yahoo
What to Expect From Universal Health Services' Next Quarterly Earnings Report
King of Prussia, Pennsylvania-based Universal Health Services, Inc. (UHS) owns and operates acute care hospitals, and outpatient and behavioral health care facilities. Valued at a market cap of $12 billion, the company's range of services include general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and behavioral health services. It is expected to announce its fiscal Q2 earnings for 2025 on Wednesday, Jul. 23. Prior to this event, analysts project this healthcare company to report a profit of $4.87 per share, up 13% from $4.31 per share in the year-ago quarter. The company has exceeded Wall Street's bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $4.84 per share in the previous quarter outpaced the consensus estimates by 11%. Is UnitedHealth Stock a Buy, Sell, or Hold for July 2025? Michael Saylor Says 'You'll Wish You'd Bought More' Bitcoin as MicroStrategy Doubles Down Is Microsoft Stock About to Go Nuclear? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the full year, analysts expect UHS to report EPS of $19.43, up 17% from $16.61 in fiscal 2024. Furthermore, its EPS is expected to grow 8.9% year-over-year to $21.16 in fiscal 2026. UHS has declined marginally over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 13% return over the same time frame. However, it has outpaced the Health Care Select Sector SPDR Fund's (XLV) 6.3% downtick over the same time period. On Apr. 28, UHS released its Q1 results, and its shares closed down marginally in the following trading session. The company's overall revenue improved 6.7% year-over-year to $4.1 billion but fell short of the consensus estimates by nearly 1%. Meanwhile, on the earnings front, due to favorable pricing and margin improvement, the company's adjusted EPS surged 30.8% year-over-year to $4.84 and surpassed the analyst estimates by 11%. Wall Street analysts are moderately optimistic about UHS' stock, with a "Moderate Buy" rating overall. Among 19 analysts covering the stock, eight recommend "Strong Buy," and 11 advise 'Hold.' The mean price target for UHS is $226.19, which indicates a 22.6% potential upside from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Daily Mail
01-07-2025
- Business
- Daily Mail
Guy Fieri faces lawsuit from Food Network reality show winner over failed restaurant
Celebrity chef Guy Fieri is facing a lawsuit over a failed restaurant that launched as a result of one of his reality shows. The 57-year-old chef launched Food Network's Guy's Chance of a Lifetime in early January 2022, where seven chefs were pitted against each other for a chance to run their own Chicken Guy franchise, one of Fieri's brands. Kevin Cooper, a chef from Philadelphia, was named the winner, with his winner's package also set to include a $100,000 guaranteed salary for the first year, along with a waived franchise fee, $10,000 set aside for any legal expenses plus assistance with the build-out space and operational expenses that exceeded revenue in the first year. Cooper's Chicken Guy franchise did open at the King of Prussia Mall outside Philadelphia back in early February 2024, just before Fieri spoke out about a 30 pound weight loss, though it closed just over a year later in late February 2025. While no reason was given for the closing, Philly Mag reports that Cooper filed a lawsuit against Fieri's company's Chicken Guy LLC and Earl Enterprises LLC. Daily Mail has reached out to multiple reps for Fieri for comment and have not immediately heard back at this time. Kevin Cooper (left), a chef from Philadelphia, was named the winner, with his winner's package also set to include a $100,000 guaranteed salary for the first year, along with a waived franchise fee, $10,000 set aside for any legal expenses plus assistance with the build-out space and operational expenses that exceeded revenue in the first year The lawsuit alleges that Fieri never provided that guaranteed $100,000 salary, despite requesting it numerous times. The filing adds that he also never provided operational expenses that exceeded the shop's revenue, as promised. Those expenses totaled $69,000, with $39,000 of that for Pennsylvania sales taxes alone, according to the lawsuit. The lawsuit is seeking the $100,000 salary and expenses that were promised after winning the reality series. While Cooper hasn't directly spoken about the lawsuit, he did post a cryptic video Sunday on Instagram, where he speaks about how 'quiet' he's been on social media lately. 'I know y'all have noticed I've been a little quiet lately, not just on social media, but in general,' Cooper began. 'However, there are some blessings in the quiet, right? There were some moments where I didn't even want to speak my truth, because the version of the God that was handed down by my ancestors, wasn't the version that I came to know in my quiet space,' he admitted. 'So for a long time I held back, because I didn't want to become just another black man pushing the blame because I was done dirty,' he added. View this post on Instagram A post shared by Kevin Cooper (@chefsteek) 'I also realized that I didn't want my life wrapped in a faith that was once used to enslave my peoples,' he added. 'But by the grace of the true and living God, I didn't just heal, I forgave. I came to know the Christ before those chains. I came to know the Christ who walked across Africa before those boats came,' he said, adding Jesus was the one who 'broke chains, not the one who binded people to them.' He concluded, 'I ain't mad, I ain't angry, and I ain't even trying to make anybody look bad, man. I'm just here to let y'all know that I am completely free and now I've got something to say, so y'all stay tuned. Peace.'
Yahoo
17-06-2025
- Health
- Yahoo
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo ANDEMBRY approval expands CSL's HAE franchise and underscores the company's legacy of delivering transformational innovations to the HAE community for over four decades KING OF PRUSSIA, Pa., June 16, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) approved ANDEMBRY® (garadacimab-gxii), the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. By targeting factor XIIa, a plasma protein that plays a key role in attacks of swelling in people with HAE, ANDEMBRY inhibits the top of the HAE cascade to prevent HAE attacks. ANDEMBRY, the only treatment to offer once-monthly dosing from the start for all patients, is a subcutaneous self-injection delivered in 15 seconds or less via an autoinjector with a citrate-free formula. HAE is a rare, chronic, and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of angioedema. Attacks of HAE are often painful and can affect multiple sites of the body, including the abdomen, larynx, face, and extremities. HAE occurs in about 1 in 50,000 people of any ethnic group. "ANDEMBRY, the first monoclonal antibody discovered and developed entirely by CSL, offers people living with this life-threatening condition long-term control over their disease along with a convenient administration method," said Bill Mezzanotte, MD, Executive Vice President, Head of R&D, CSL. "ANDEMBRY underscores our long-standing and enduring commitment to better the lives of the patients we serve, including those suffering with HAE. I'd like to thank all the physicians, patients and my colleagues who contributed to this exciting milestone for HAE patients and CSL." The approval is supported by data from the pivotal placebo-controlled Phase 3 VANGUARD trial evaluating the efficacy and safety of ANDEMBRY. The pivotal study (The Lancet, April 2023) demonstrated that treatment with ANDEMBRY: Led to 62 percent of ANDEMBRY-treated patients remaining attack-free throughout the treatment period. Reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo. Achieved more than 99 percent median reduction and an 88 percent mean reduction in HAE attacks requiring on-demand therapy, compared to placebo. Attained more than 99 percent median reduction and a 90 percent mean reduction in moderate or severe attacks, compared to placebo. The most common adverse reactions in the pivotal trial (incidence ≥7%) are nasopharyngitis and abdominal pain. A published interim analysis (Allergy, Oct 2024) of the ongoing open-label extension study (median ANDEMBRY exposure of 13.8 months) showed that ANDEMBRY has a favorable long-term safety profile and provides sustained reductions in HAE attacks. In the pivotal trial and the open-label extension study, injection-site reactions (e.g., injection-site bruising, injection-site erythema, injection-site hematoma, injection-site pruritus, injection-site urticaria) were reported in 23 (14%) patients. "We've made significant progress in treating hereditary angioedema, yet many patients still experience painful and sometimes life-threatening HAE attacks and require frequent injections to manage them," said Dr. Tim Craig, Professor of Medicine, Pediatrics and Biomedical Sciences at Penn State University. "We now have a new option to manage this condition through a new target, as it allows us for the first time to inhibit the top of the HAE cascade by targeting factor XIIa." "ANDEMBRY, a novel once-monthly subcutaneous treatment that inhibits factor XIIa, is a welcome addition to the HAE treatment landscape," said Anthony J. Castaldo, CEO and Chairman of the Board, US HAE Association and HAE International. "People with HAE now have another choice for lessening the burden associated with this lifelong condition and realizing the community's shared goal of experiencing life to the fullest." This regulatory approval for ANDEMBRY is another crucial step in building toward the global availability of ANDEMBRY, which was recently approved in Australia, the United Kingdon (UK), the European Union (EU), Japan, Switzerland, and United Arab Emirates. CSL Behring will launch ANDEMBRY commercially immediately, with availability before the end of June. Healthcare professionals and patients interested in learning more about ANDEMBRY or accessing the therapy are encouraged to utilize ANDEMBRY ConnectSM, designed to offer comprehensive support and assistance through various programs. For more information, call 844-423-4273 or visit About HAE HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE is caused by deficient or dysfunctional C1INH, a protein in the blood that helps to control inflammation. Inadequate amounts of properly functioning C1INH can lead to the accumulation of fluid in body tissues, causing considerable swelling referred to as angioedema. HAE attacks can affect many parts of the body, including the face, abdomen, larynx, and extremities. Patients who have abdominal attacks of HAE can experience extreme pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if left untreated, death. About ANDEMBRYANDEMBRY is a novel monoclonal antibody inhibiting factor XIIa (anti-FXIIa mAb) that has completed the Phase 3 pivotal study as a new type of once-monthly subcutaneous prophylactic treatment for attacks related to HAE, a form of bradykinin-mediated angioedema. ANDEMBRY is CSL's first homegrown recombinant monoclonal antibody to gain FDA approval. It was discovered and optimized by scientists at CSL's Bio21-based research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility. ANDEMBRY uniquely inhibits the plasma protein, FXIIa. FXII is the first protein activated in the HAE pathway, initiating the cascade of events leading to an HAE attack. By targeting activated FXII (FXIIa), ANDEMBRY inhibits this cascade at the top as compared to other HAE therapies that target downstream mediators. About the VANGUARD Trial The multicenter, randomized, double-blind, parallel-group VANGUARD trial evaluated the efficacy and safety of ANDEMBRY, an investigational first-in-class monoclonal antibody, as a prophylactic treatment for patients with hereditary angioedema. Patients aged 12 years and older with HAE type I or II underwent screening and a run-in study period to verify a baseline attack rate. Patients were randomized 3:2 to receive a loading dose of 400 mg followed by 200 mg of ANDEMBRY monthly (n=39) or volume matched placebo monthly (n=25) subcutaneously. After the six-month treatment period, patients were given the opportunity to continue into the open-label extension study, which is currently ongoing. The ongoing open-label extension of the Phase 3 VANGUARD study is evaluating the long-term safety and efficacy of ANDEMBRY (200 mg monthly) for the prophylactic treatment of hereditary angioedema attacks. IMPORTANT SAFETY INFORMATION What is ANDEMBRY?ANDEMBRY® (garadacimab-gxii) injection, for subcutaneous use, is a prescription medication used to prevent attacks of hereditary angioedema (HAE) in people 12 years and older. It is not known if ANDEMBRY is safe and effective in children under 12 years of age. What should I tell my healthcare provider before using ANDEMBRY?Before using ANDEMBRY, tell your healthcare provider about any medical condition you may have, especially if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. It is not known if ANDEMBRY can harm your unborn baby or if ANDEMBRY passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while using ANDEMBRY. Tell your healthcare provider about all medications you take, including prescription medicines, over-the-counter treatments, vitamins, and herbal supplements. How should I use ANDEMBRY? Use ANDEMBRY exactly as instructed by your healthcare provider. Detailed instructions for use can be found in the patient information section of the full prescribing information. ANDEMBRY is given as an injection under your skin (subcutaneous) by you or a caregiver. Your healthcare provider should show you or your caregiver how to prepare and inject your dose of ANDEMBRY before you inject yourself for the first time. Do not try to inject ANDEMBRY unless you have been trained by your healthcare provider. What are the possible side effects of ANDEMBRY?The most common side effects of ANDEMBRY include: Redness, itchiness, and bruising (injection-site reactions) Stomach (abdominal) pain Runny or stuffy nose, sneezing, watery eyes (nasopharyngitis) Please see full prescribing information for ANDEMBRY, including patient information and instructions for use. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958. About CSLCSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL, visit Media ContactsValerie BombergerCSLOffice: +1 610-291-5388 Mobile: +1 267-280-3829 Email: Etanjalie Ayala CSL Behring Mobile: +1 610 297 1069 Email: Greg HealyCSLMobile: +1 610-906-4564Email: In Australia: Kim O'DonohueCSLMobile: +61 449 884 603Email: Brett FoleyCSLMobile: +61 461 464 708 Email: Investors ContactChris CooperCSLMobile: +61 455 022 740Email: View original content to download multimedia: SOURCE CSL Sign in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
Vertex Named a Finalist for 2025 SAP® Pinnacle Award in the SAP Store Category
KING OF PRUSSIA, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) ('Vertex' or the 'Company'), a global provider of tax technology solutions, today announced that it has been recognized by SAP as a finalist for a 2025 SAP® Pinnacle Award in the SAP Store category. The annual SAP Pinnacle Awards acknowledge the contributions of leading SAP partners that have excelled in developing and growing their partnership with SAP and helping customers meet their goals. Finalists and winners in 24 categories were chosen based on recommendations from SAP, customer feedback and performance indicators. 'Our recognition as a Pinnacle Award finalist reflects the strength of our partnership with SAP and our shared commitment to customer success,' said Brian Wilchusky, Senior Director of SAP Global Partnerships at Vertex. 'Together, we're delivering integrated solutions that help businesses simplify tax complexity, drive growth and achieve lasting value.' The SAP Pinnacle Awards celebrate leading partners that help customers become best-run businesses through SAP's innovative technologies. This award specifically recognizes a partner that demonstrates success in showcasing innovative solutions on SAP Store and delivering value at scale across the customer lifecycle. Evaluation criteria include solution visibility, opportunity creation, and pipeline impact. With more than 25 years of collaboration, Vertex and SAP have delivered trusted, integrated tax solutions that drive business performance. The Company will also participate in and sponsor the SAP Sapphire conference, reinforcing its strategic investment in the SAP partner ecosystem. SAP Pinnacle Awards shine a spotlight on distinguished partners to acknowledge their dedication to teamwork, exceptional innovation and capacity to help customers achieve their goals. To learn more about the Vertex and SAP partnership, visit our partner page. About Vertex Vertex, Inc. is a leading global provider of indirect tax solutions. The Company's mission is to deliver the most trusted tax technology enabling global businesses to transact, comply and grow with confidence. Vertex provides solutions that can be tailored to specific industries for major lines of indirect tax, including sales and consumer use, value added and payroll. Headquartered in North America, and with offices in South America and Europe, Vertex empowers the world's leading brands to simplify the complexity of continuous compliance. For more information, visit or follow us on X and LinkedIn. COPYRIGHT © 2025 VERTEX, INC. ALL RIGHTS RESERVED. THE INFORMATION CONTAINED HEREIN IS INTENDED FOR INFORMATION PURPOSES ONLY, MAY CHANGE AT ANY TIME IN THE FUTURE, AND IS NOT LEGAL OR TAX ADVICE. SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies. Vertex Company Contact:Rachel Litcofsky Manager, Public Relations mediainquiries@
